

Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers

Guest Editor:

Assoc. Prof. Dr. Veysel Kayser

School of Pharmacy, Faculty of
Medicine and Health, The
University of Sydney, Sydney,
Australia

veysel.kayser@sydney.edu.au

Deadline for manuscript
submissions:

31 July 2019

Message from the Guest Editor

Dear Colleagues,


Therapeutic monoclonal antibodies (mAbs) are not only dominating the current biologics market but also the mainstay for the development of next-generation biologics as a result of their specificity and selectivity.

This Special Issue will cover all aspects of the design, development and optimization of therapeutic monoclonal antibodies. In addition, studies related to protein structure, formulation, pharmacodynamic/pharmacokinetic, immunogenicity, accelerated and prediction results will also be considered. Both experimental and computational approaches can be submitted.

Keywords

- mAbs / Antibody Optimization / Characterization of Antibodies
- Antibody Medicines / Antibody–Drug Conjugates (ADC)
- Bispecific Antibodies / Multispecific Antibodies
- Next-generation Biologics / Single-domain Antibodies (Nanobodies)
- Follow-on Biologics / Formulation of mAbs
- Biosimilars / Biobetters / Engineering of Antibodies
- Pharmacokinetic and Pharmacodynamic Studies of mAbs
- Modeling and simulation of antibody clearance
- Accelerated Studies of mAbs
- Prediction of Long-term Behavior of mAbs
- Simulation and Experimental Studies of mAbs





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science) and BIOSIS Previews. Citations available in PubMed, full-text archived in PubMed Central. Indexed in BIOSIS Previews, Scopus and other databases.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 16.9 days after submission; acceptance to publication is undertaken in 4.2 days (median values for papers published in this journal in the second half of 2018).

Contact Us

Cancers
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
@Cancers_MDPI